article thumbnail

STAT+: Biden administration makes opening offers in Medicare drug price negotiations

STAT

WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

article thumbnail

STAT+: Biden administration axes proposal to mandate more drug price transparency in Medicaid

STAT

Biden administration officials have abandoned their own proposal to require drug companies to disclose the prices and research costs of drugs that are driving up spending in state Medicaid programs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Mid-year drug price hikes are back despite Inflation Reduction Act

STAT

At the start and halfway points of each year, many pharmaceutical companies raise drug prices to bolster revenue and reportedly fund new research. “It’s not just all selling new drugs,” said Juliette Cubanski, deputy director of the Program on Medicare Policy at Kaiser Family Foundation.

article thumbnail

STAT+: Congress’s PBM reforms won’t end America’s drug pricing woes. Here’s what they would do

STAT

They’re focused this summer on reining in pharmacy middlemen to make the system fairer — but none of their many proposals will actually tackle the core dynamic that has incentivized higher drug prices. Pharmacy benefit managers are companies employed by insurers to negotiate lower drug costs with pharmaceutical companies.

article thumbnail

STAT+: Pharmalittle: Court allows Medicare drug price negotiation to proceed; J&J will not enforce patents on key TB drug

STAT

… A federal court judge allowed the new Medicare drug price negotiation program to proceed while the court deliberates whether it is constitutional , STAT reports. Meanwhile, Novo Nordisk became the latest pharmaceutical company to file a lawsuit against the Medicare drug price negotiation program , Bloomberg Law tells us. The

article thumbnail

STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices

STAT

But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work. Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid.

article thumbnail

Watch: How drug patents pave the way to profit

STAT

This is Part 3 of “Behind the Counter,” an in-depth video series demystifying the complex world of patents and drug pricing. Discovering a new drug is a big win for a pharmaceutical company, but selling it for lots of money with no competition? The cherry on top. Read the rest…